Products

23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia
23andMe
Clinical Decision Support & Reference
It provides personal genetic insights for proactive health discussions with healthcare professionals.

See all 1 product →

About 23andMe

23andMe is a pioneering personal genomics and biotechnology company that offers direct-to-consumer genetic testing. The company’s core service involves analyzing saliva samples to provide individuals with reports on their ancestry, genetic predispositions to health-related conditions, carrier status for family planning, wellness and lifestyle factors, and how their bodies may process certain medications. While not a diagnostic tool, these reports aim to empower individuals to take a more active role in their health by providing valuable genetic insights for informed decisions and proactive health management.

Beyond its consumer services, 23andMe maintains a significant research arm. The company has built one of the world’s largest crowdsourced platforms for genetic research, with a substantial percentage of its customers consenting to participate. This extensive database has been instrumental in hundreds of peer-reviewed publications across various disease areas, including Parkinson’s disease, depression, COVID-19, autoimmune diseases, and pharmacogenomics. 23andMe also has a Therapeutics group that leverages human genetic data to accelerate drug discovery programs in areas such as oncology, respiratory, and cardiovascular diseases.

Following its bankruptcy, the company’s assets were acquired by TTAM Research Institute, a nonprofit public benefit corporation, and it continues to operate as a nonprofit.

Focus Areas

Direct-to-consumer genetic testing personal genomics genetic health risk assessment ancestry analysis pharmacogenetics drug discovery genetic research telehealth

Business Intelligence

TechnologyGenotyping technology using a custom version of the Illumina Global Screening Array to analyze specific genetic variants. The platform tests hundreds of thousands of variants to generate reports on ancestry and genetic predispositions.

What Physicians Need to Know

Direct-to-Consumer Genetic Testing
23andMe offers direct-to-consumer (DTC) genetic testing services, allowing individuals to access information about their DNA from home without a medical requisition. Their Personal Genetic Service provides tools and information for individuals to learn about their DNA, covering ancestry, health predispositions, carrier status, pharmacogenetics, and wellness.
Genetic Health Risk Assessment
23andMe provides reports on genetic health risks, including predispositions to certain conditions and carrier status for inherited conditions. These reports are designed to deliver genetic information in an engaging and responsible way, and in certain cases, can offer valuable information for clinical management. They are the first and only DTC genetic test to include FDA-authorized Genetic Health Risk, Cancer Predisposition, Carrier Status, and Pharmacogenetics reports.
Ancestry Analysis
The company offers comprehensive ancestry breakdowns, providing insights into an individual's genetic origins across numerous geographic regions and assembling a timeline of genetic ancestry.
Pharmacogenetics
23andMe provides pharmacogenetics reports that explain how an individual's DNA may influence how their body processes certain medications. These reports are FDA-authorized and meet similar FDA standards of clinical and analytical validity as their other health reports.
Drug Discovery & Genetic Research
Beyond direct-to-consumer testing, 23andMe engages consumers in research to accelerate therapeutic development, with approximately 80% of their customers consenting to participate. Their research institute uses human genetic data to contribute to major breakthroughs in medical research and drug discovery.
Telehealth
With Lemonaid Health now part of the 23andMe family, customers can connect with a provider in any U.S. state for a Genetic Report Consultation on certain 23andMe Health reports.
Physician Tip

23andMe's reports are not intended as diagnostic tools but can provide valuable information for clinical management, especially for health predispositions, pharmacogenetics, and carrier status. Nearly 30% of consumers share their reports with healthcare providers to inform health conversations. When patients share results, it often leads to medical recommendations, with a high adherence rate. Physicians should be aware that 23andMe utilizes genotyping technology, specifically a custom Illumina Global Screening Array, to detect specific genetic variants. While the reports are designed for user comprehension, it's crucial for healthcare professionals to understand the intended use, limitations, and relevant ethnicities highlighted in the reports. Educational resources for healthcare professionals are available on the 23andMe website, including sample reports and webinars. Encourage patients to share their results, as this can lead to personalized care and preventive actions.

23andMe allows users to download their raw DNA data. This raw data can then be uploaded to third-party sites like MyHeritage, FamilyTreeDNA, and GEDmatch for expanded genealogical analysis and DNA matching beyond the 23andMe database. While 23andMe does not accept outside DNA files, users can merge their 23andMe data with other sources for personal projects. Genealogy Assistant, a third-party tool, also supports 23andMe, allowing users to group DNA matches and utilize surname comparison tools.

Products by 23andMe

1 product in the directory

23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia
23andMe
Clinical Decision Support & Reference
It provides personal genetic insights for proactive health discussions with healthcare professionals.

Videos

News, demos, and interviews about 23andMe.

Loading videos...

Videos load interactively. If none appear, search YouTube for 23andMe →

View all on YouTube

No press coverage or publications on file yet. Know of some? Suggest an edit →

Frequently Asked Questions

23andMe provides reports on an individual's genetic predisposition to certain health conditions, such as Parkinson's disease, late-onset Alzheimer's disease, and celiac disease, as well as carrier status for conditions like cystic fibrosis. While these assessments can offer insights into potential risks, they are not intended to diagnose or treat any disease and should be interpreted in the context of a patient's full medical history and with professional medical advice. The clinical utility and reliability for direct clinical decision-making are areas of ongoing discussion and research within the medical community.
23andMe employs various security measures to protect customer data, including encryption, strict access controls, and adherence to relevant privacy regulations. Users have control over their data and can choose whether to participate in research or share their information. However, as with any online service handling sensitive data, physicians and healthcare administrators often have concerns about the potential for data breaches and the long-term implications of genetic data storage and usage, particularly in the context of evolving privacy landscapes.
23andMe has established partnerships with pharmaceutical companies and research institutions to leverage its vast genetic database for drug discovery and genetic research. These collaborations aim to identify new drug targets, understand disease mechanisms, and accelerate therapeutic development. Customer participation in such research is typically opt-in, meaning individuals must explicitly consent to their de-identified data being used for these purposes, raising questions about informed consent and the commercialization of genetic information.
23andMe offers pharmacogenetic reports that provide insights into how an individual's genetics may influence their response to certain medications, such as some antidepressants and pain medications. While these insights can be a valuable tool for personalized medication management, they are not comprehensive and should be used in conjunction with a physician's clinical judgment, patient history, and other diagnostic information. The integration into routine clinical practice requires careful consideration of the scope of the reports and the need for confirmatory testing in some cases.
23andMe provides some resources for healthcare professionals, including informational materials and webinars, to help them understand the scope and limitations of their reports. However, the primary responsibility for interpreting results and integrating them into patient care lies with the physician. Healthcare administrators often inquire about more robust educational programs, direct physician support lines, and clear guidelines for clinical interpretation to ensure responsible use of the data.
23andMe's business model primarily revolves around direct-to-consumer genetic testing, but it also generates revenue through partnerships with pharmaceutical companies for drug discovery and research. Healthcare administrators and potential partners often assess the company's financial stability, profitability, and long-term viability to ensure it can sustain its services and commitments. This includes evaluating its market position, investment in research and development, and ability to navigate the evolving regulatory and competitive landscape of the genomics industry.
23andMe provides disclaimers and educational materials to help consumers understand the limitations and implications of their genetic results, particularly for health risks and ancestry. They emphasize that results are for informational purposes and not a substitute for professional medical advice. However, concerns remain among healthcare professionals about the potential for misinterpretation, anxiety, or inappropriate actions taken by consumers based on their results, highlighting the need for clear communication and access to genetic counseling.

Investors

Who's funded 23andMe.

Related Companies

Radin Health offers a comprehensive suite of AI-powered, cloud-based solutions designed to enhance operational efficiency across all stages of the radiology workflow. Their platform integrates a Radiology Information System (RIS), Picture Archiving and Communication System (PACS), AI-driven Dictation, and RADIN SELECT for workflow management. These solutions aim to improve efficiency and productivity for administrators, medical […]

Google Workspace provides a comprehensive suite of secure online productivity and collaboration tools designed for various organizational sizes, including businesses, enterprises, and frontline workers. For physicians and healthcare professionals, Google Workspace offers a secure environment for communication, data storage, and document management, which is crucial for maintaining patient confidentiality and operational efficiency. The platform integrates […]

Pacmed is an Amsterdam-based clinical intelligence company that develops and implements AI solutions to improve hospital care, with a particular focus on the Intensive Care Unit (ICU). The company’s core product, Pacmed Critical, is an AI platform designed to optimize ICU capacity, enhance patient outcomes, and provide data-driven insights for medical professionals. This platform integrates […]

AiZtech Labs is a pioneering deep tech company that leverages AI to transform healthcare by providing accessible and rapid screening tools. Their mission is to enhance the quality of life for one billion people by blending world-class AI research with human-centered design. The company’s flagship platform, iSelfie BioSignals, utilizes a smartphone camera to detect digital […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.